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Assessment of Personality Disorder in Adult ADHD Using Data from a Clinical Trial of 
OROS Methylphenidate (OROS MPH)
ABSTRACT:
Background: Studies have reported high comorbidity of
personality disorder and adult ADHD. However, assessment of
personality disorder is problematic and none have rigorously
confirmed this observation with measures of concurrent validity.
Methods: 47 patients entered a double-blind trial of OROS
MPH after administration of the Wisconsin Personality
Inventory (WISPI-IV) and the SCID-II. At discharge, all
information was reviewed to produce a final consensus
personality diagnosis. Patients were separated into three post
hoc categories: PDnegative (no personality disorder),
PDpositive (subjects meeting diagnostic criteria for one
disorder), and PDplus (subjects meeting diagnostic criteria for
≥2 disorders).
Results:  45% of subjects had a personality disorder on the final 
assessment versus 62% (SCID-II) and 33% (WISPI-IV): 11% 
cluster A, 17% cluster B and 30% cluster C. Compared to the 
final assessment, the WISPI-IV identified PDnegative subjects 
with sensitivity = .92 and specificity = .67 and PDplus subjects 
with sensitivity = .40 and specificity = 1.00. The SCID-II 
identified PDnegative subjects with sensitivity = .64 and 
specificity = .90 and PDplus subjects with sensitivity = .90 and 
specificity = .84. There was a significant correlation between the 
number of SCID-II items endorsed by each subject and their 
WISPI-IV average z-score (r=.67, df=46, p<.001).
Conclusions:  All three systems detected personality disorder 
in a large proportion of patients. The WISPI tended to under-
estimate personality disorders while the SCID-II over-estimated 
them. The self-administered WISPI-IV would be more practical 
in a multicenter clinical trial to provide an estimate of 
personality disorder. 
Light therapy has been demonstrated useful in treating SAD. The 
seminal article by Rosenthal et al (1984) hypothesized about the 
depressogenic effects of melatonin and described preliminary findings 
about the effects of artificial light therapy. Since that time, research has 
supported this observation and expanded to conditions other than SAD 
such as problems with jet-lag and shift work. A particular area of interest 
is the relationship between SAD and other affective disorders. It is 
probable that even within SAD studies, subjects do not all suffer from 
pure SAD, but most studies do not indicate the degree of overlap in their 
samples. For example, patients with major depressive disorder often 
have seasonal variations with winter being the season with the greatest 
risk for depression (Kasper et al 1990).
Photosensitive retinal ganglion cells that project from the retina to the
suprachiasmatic nucleus, intergeniculate leaflet and olivary pretectal
nucleus (Gooley et al 2003) are probably responsible for the melatonin
suppression associated with light therapy. It appears that these cells
respond most strongly to wavelengths of ~480nm. This understanding 
has led to the development of blue light therapy for SAD.
While blue light treatment of SAD has proven effective in prior trials, the
present study was an improvement in three ways: 1) The use of bright 
red light as placebo rather than the commonly used dim red light. 2) The 
impact of incomplete summer remission on treatment outcome was 
assessed. 3) An open-label, follow-up period was included.
This was a 3-week, parallel, controlled, double-blind trial of bright blue light in the 
treatment of SAD conducted during January and February 2006.  Subjects were 
categorized post hoc into those with evidence of comorbid major depression based on 
subjects’ past history and/or ongoing use of antidepressant medication (SAD or 
SAD+MDD).  Although subjects could not be blind regarding the color of their light 
panel, they were blind regarding the hypothesis that blue would be effective and red 
ineffective.  All subjects who completed the double-blind trial were given an 
opportunity to enter into a 4-week open-label trial of blue LED light treatment.
Patient eligibility:
Met criteria for Seasonal Affective Disorder plus a baseline SIGH-SAD score ≥20
Outpatients 18 years or older
General good health without photosensitive conditions
No recent use of light therapy and no past failed treatment of light therapy
Equipment:
The light treatment units were designed and produced by the sponsor of this study: 
Apollo Light Systems, Orem, Utah.  The active unit was a 470 nm blue LED light unit 
and the placebo unit was a 650 nm red LED unit.  While the photon densities of the 
two panels were not the same, their visual intensities were very similar.  The 
brightness of the red panel increased its credibility as a placebo treatment.
Data analysis:
Efficacy in the double-blind period was assessed using repeated measures-ANOVA 
(baseline to end-point) for continuous variables and Fisher’s exact test for categorical 
variables (LOCF).  Efficacy in the open-label period was assessed two ways:  1) 
Comparing the open-label outcome with baseline.  2) Separate comparisons of open-
label to double-blind for the two treatment groups using paired t-test for continuous 
variables and Fisher’s exact test for categorical variables.
Baseline:
As seen in Table 1, the two double-blind treatment groups were very similar except for age.




Improvement in HAM-D scores: mean±sd (%) improvement over baseline
HAMD-17 6.0±3.9 (32%) 10.1±5.3 (51%) .05
SIGH-SAD Total 10.2±10.7 (21%) 15.7±9.6 (40%) .15
Categorical Improvement: N (%) improved 
CGI-I ≤2 2 (13%) 9 (60%) .01
CGI-S ≤3 2 (13%) 9 (60%) .01
HAMD-17b 2 (13%) 8(53%) .05
a) p-Values were calculated (LOCF) using a repeated measures ANOVA procedure for continuous 
variables and the Fisher exact test for categorical variables.
b) Subjects experiencing at least a 50% improvement in HAMD-17 scores were categorized as 
improved.
Open-Label:
All subjects who completed the double-blind trial were given an opportunity to enter into a 4-
week open-label trial of blue-light treatment.  Change from baseline to endpoint was 
dramatic for these subjects.  Subjects improved 64% on HAMD-17 scores (F1,21=120.6, 
p<.001) and 73% on SIGH-SAD scores (F1,21=112.7, p<.001).  As seen in Table 3, subjects 
from the placebo group showed statistically significant improvement over the double-blind 
period in all reported measures.  In contrast, subjects from the blue-light group showed 
minor, nonsignificant improvement in all measures.  By the end of the open-label phase, the 
two groups did not differ significantly on any measure.
Adverse Events and Side Effects:
Blue LED light therapy was similar to red LED light therapy in the 
incidence of adverse events and side-effects.  In the course of this study 
(both double-blind and open-label phases) 10 subjects reported a total of 
17 adverse events or side effects during blue-light therapy.  One subject 
discontinued treatment because of photosensitivity.  This subject was in 
the blue-light arm, and left the study after one week double-blind 
treatment.  There were five reports of headaches; two reports each of 
sleep disturbance and eye irritation; and one report each of: light 
headed/dizzy, upper respiratory infection, sunburn, photosensitivity, 
nausea, odd dreams, memory problems, and dysphoria.  Nine of these 
problems were described as mild and eight were described as moderate.
Blue-light therapy proved effective in treating Seasonal Affective 
Disorder.
Bright red-light therapy proved to be an effective placebo condition, 
suggesting that future research should consider it in place of dim red-
light as a placebo.
 Incomplete summer remission (SAD+MDD) was associated with lower 
responses to treatment in the double-blind period.  However, 67% of 
these subjects had responded to treatment by the end of the open-label 
condition.
Side effects were similar in the two treatment conditions and similar to 
past bright-light studies with one subject discontinuing treatment 
because of photosensitivity.
These results support biological studies implicating photosensitive 
retinal ganglion cells and melatonin suppression in the treatment of 
seasonal affective disorder.
This study was underpowered to fully address potential differences 
between the SAD and SAD+MDD samples.  Larger studies are needed.
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Table 1: Characteristics at baseline for both double-blind groups and all subjects 
entering open-label treatment.
Red-Light Blue-Light Open-Label
N 15 15 25
Age (years) 39.5±9.9 51.1±12.3 45.6±12.5
Female n(%) 13(87%) 10(67%) 19(76%)
HAMD-17 19.7±5.1 20.3±3.7 20.0±4.7
SIGH-SAD 34.1±5.9 34.1±5.6 33.9±6.0
SAD+MDD 4(27%) 7(47%) 8(32%)
SAD alone and SAD+MDD differences:
On the HAMD-17, the 19 subjects with pure SAD improved an average of 32% in the red-
light arm and 61% in the blue-light arm, a difference that approached significance (p=.08).  
Further, 63% of them met CGI-I criteria for improvement in the blue-light arm, while 18% 
improved in the red-light arm (Fisher exact test =.074).  The 11 subjects with SAD+MDD 
improved an average of 30% in the red-light arm and 40% in the blue-light arm, a difference 
that was not significant (p=.70).  However, 57% of them met CGI-I criteria for improvement 
in the blue-light arm while none improved in the red-light arm (Fisher exact test =.194).
Table 3: Outcome measures at baseline, double-blind and open-label for subjects 
entering the open-label phase.  Data are presented using LOCF within each phase.
Baseline Double-Blind Open-Label p-Valuea
Red-Light Group N=13
HAMD-17 19.4±5.3 13.2±5.7 6.5±7.9 .022
CGI-I ≤2 na 2(15%) 11(85%) .001
Blue-Light Group N=12
HAMD-17 20.6±4.0 9.8±6.7 8.0±7.1 >.50
CGI-I ≤2 na 8(67%) 10(83%) >.50
a) p-Values compare open-label with double-blind scores (LOCF).  Continuous data 
were assessed using paired t-tests and categorical data were assessed using the 
Fisher exact test.
SAD alone and SAD+MDD differences:
Both subjects with SAD alone and SAD+MDD showed statistically 
significant improvement by the end of the open-label phase.  These 
analyses include all subjects with any blue-light treatment (including 
those who did not enter the open-label period).  On the HAMD-17 the 16 
subjects with SAD alone improved 71% over baseline (p=.001), while the 
12 subjects with SAD+MDD improved 56% (p=.005)(LOCF).  Similarly, 
88% of subjects with SAD alone met CGI-I criteria for improvement while 
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Double-Blind:
Blue-light therapy proved significantly more effective than red-light in every outcome 
measure except SIGH-SAD scores:  HAMD-17 (F1,26=4.52, p=.043); SIGH-SAD 
(F1,26=2.19, p=.15); CGI-I (Fisher’s exact test p=.01); CGI-S (Fisher’s exact test p=.01).
Fig 1.  Average HAMD-17 Scores for the Two 
Double-Blind Treatment Groups During the 
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